TY - JOUR
T1 - Late-Onset Fulminant Myocarditis With Immune Checkpoint Inhibitor Nivolumab
AU - Yamaguchi, Shogo
AU - Morimoto, Ryota
AU - Okumura, Takahiro
AU - Yamashita, Yuta
AU - Haga, Tomoaki
AU - Kuwayama, Tasuku
AU - Yokoi, Tsuyoshi
AU - Hiraiwa, Hiroaki
AU - Kondo, Toru
AU - Sugiura, Yuki
AU - Watanabe, Naoki
AU - Kano, Naoaki
AU - Kohno, Kei
AU - Fukaya, Kenji
AU - Sawamura, Akinori
AU - Yokota, Kenji
AU - Ishii, Hideki
AU - Nakaguro, Masato
AU - Akiyama, Masashi
AU - Murohara, Toyoaki
N1 - Publisher Copyright:
© 2018 Canadian Cardiovascular Society
PY - 2018/6
Y1 - 2018/6
N2 - A 60-year-old man was diagnosed with melanoma. After receiving 13 infusions of nivolumab, he had fulminant myocarditis. The myocardial biopsy specimen revealed extensive lymphocytic infiltration, interstitial edema, and myocardial necrosis, with predominant CD4+, CD8+, CD20− and programmed death-1− markers. Programmed death-1 ligand 1 (PD-L1) was predominantly expressed on the surface of the damaged myocardium. Although it is reported that myocarditis induced by the human anti-programmed death-1 inhibitor nivolumab therapy rarely occurred at > 2 months use in clinical trials, this case showed that even if at a late phase, long-term use of immune checkpoint inhibitors might to lead immune-related adverse events including myocarditis.
AB - A 60-year-old man was diagnosed with melanoma. After receiving 13 infusions of nivolumab, he had fulminant myocarditis. The myocardial biopsy specimen revealed extensive lymphocytic infiltration, interstitial edema, and myocardial necrosis, with predominant CD4+, CD8+, CD20− and programmed death-1− markers. Programmed death-1 ligand 1 (PD-L1) was predominantly expressed on the surface of the damaged myocardium. Although it is reported that myocarditis induced by the human anti-programmed death-1 inhibitor nivolumab therapy rarely occurred at > 2 months use in clinical trials, this case showed that even if at a late phase, long-term use of immune checkpoint inhibitors might to lead immune-related adverse events including myocarditis.
UR - https://www.scopus.com/pages/publications/85047440701
UR - https://www.scopus.com/pages/publications/85047440701#tab=citedBy
U2 - 10.1016/j.cjca.2018.03.007
DO - 10.1016/j.cjca.2018.03.007
M3 - Article
C2 - 29801747
AN - SCOPUS:85047440701
SN - 0828-282X
VL - 34
SP - 812.e1-812.e3
JO - Canadian Journal of Cardiology
JF - Canadian Journal of Cardiology
IS - 6
ER -